Singapore, July 17 -- GC Biopharma, a South Korean pharmaceutical company, has announced that its varicella vaccine BARYCELA has received marketing authorisation from the Drug Administration ofVietnam(DAV).

Following domestic approval in 2020 and WHO Pre-Qualification (PQ) in 2023, GC Biopharma has been accelerating individual country registrations as part of its dual-track strategy, pursuing both global procurement channels and direct market entry initiatives.

To obtain approval inVietnam, GC Biopharma conducted local clinical trials to establish the product's safety and immunogenicity. This achievement highlights the company's ability to meet the increasingly stringent regulatory standards set by DAV. As a vaccine administered primari...